Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended phase 2 dose and overall safety and
tolerability of TRC105 when given in combination with capecitabine for the treatment of
patients with progressive or recurrent metastatic breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Tracon Pharmaceuticals Inc.
Collaborators:
Roswell Park Cancer Institute United States Department of Defense